Rare drug makes human blood deadly to mosquitoes: Study
(NewsNation) — The deadliest animal in the world is the pesky blood sucking mosquito, killing an estimated 700,000 people a year, according to the Centers for Disease Control and Prevention.
But a new study published Wednesday suggests that a rare medication has the potential to make human blood deadly to mosquitoes, offering a new way to treat deadly diseases like malaria, West Nile virus, yellow fever and Dengue fever.
Dr. Omer Awan, a physician and a professor at the University of Maryland School of Medicine, joined 'Morning in America' to discuss nitisinone, an FDA-approved drug used to treat rare metabolic diseases.
Now, the drug could be used to treat malaria.
Trump administration to end funding for vaccinating children in poor countries
'The way it works is that it prevents a mosquito's ability to digest its blood meal, and that will kill a mosquito very quickly, so it could potentially be a game changer when you consider just how common malaria is,' Awan said.
An estimated 263 million malaria cases were reported worldwide in 2023, according to the World Health Organization, and 597,000 people died from the disease caused by mosquitoes.
'This is really starving the mosquito. That's literally what it's doing, so they will die within hours,' Awan said.
The researchers in the study compared mosquitoes that were given human blood that had nitisinone versus blood that did not.
'Even at low therapeutic doses, nitisinone remained deadly to mosquitoes,' the study said. 'These findings warrant further investigation of nitisinone for vector control and the prevention of malaria transmission.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
West Nile Virus detected in New Orleans mosquitoes, city expands control measures
NEW ORLEANS (WGNO) — The city of New Orleans has detected West Nile virus in mosquito populations across multiple neighborhoods, prompting an increase in spraying and public health outreach as mosquito season hits its peak. No human cases have been reported so far, but officials say the presence of the virus in local mosquito traps is a clear warning sign. 'We are collecting mosquitoes every Monday and Tuesday,' said Claudia Riegel, Director of the City's Mosquito, Termite, and Rodent Control Board. 'We're monitoring which species are present and whether they're carrying any viruses that could impact our residents or even their pets.' City of New Orleans, Orleans Parish School Board back in court involving $90M negotiation In response, mosquito control crews are actively treating neighborhoods by both truck and helicopter, using a combination of larvicide and adulticide to disrupt breeding and reduce adult mosquito populations. The city currently maintains 89 trap locations, where mosquito samples are tested weekly for West Nile, Eastern Equine Encephalitis and St. Louis Encephalitis. Officials stress that even small amounts of standing water, inside trash bins, tires, clogged gutters or yard debris can serve as mosquito breeding grounds. 'We want to make sure that when people put debris out, they bag it tightly so no water collects inside,' said Matt Torri with the city's Department of Sanitation. Health officials also caution that while most people infected with West Nile won't experience symptoms, a small percentage can become seriously ill. 'Roughly four out of five people will have no symptoms at all,' said Meredith McInturff with the New Orleans Health Department. 'But for the unlucky one in five, symptoms can include fever, fatigue and respiratory issues that last for several days or even weeks.' The city recommends using EPA and CDC approved mosquito repellents, emptying containers that hold water and keeping yards clear of debris. Residents can report mosquito problems or request tire pickup and additional trash bins by calling mother suspects foul play in daughter's Riverwalk death West Nile Virus detected in New Orleans mosquitoes, city expands control measures Two killed in Jefferson Parish car crash Hardline House conservatives swing for fences in asks to Senate GOP on megabill Start times for Men's College World Series revealed Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Health New England to replace Humira coverage with lower-cost biosimilars
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health plans. Markey playing defense against GOP clean energy plans Effective July 1, the not-for-profit health insurer will cover Amjevita by Nuvaila and Hadlima instead of Humira, as part of a broader effort to manage rising health care costs while maintaining access to effective treatments. Humira is used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. 'Biologic medications like Humira are complex treatments that carry significant cost. Its biosimilars provide a meaningful opportunity to enhance affordability for the health care ecosystem while members continue to get the full benefits of the medication,' said Gary Tereso, PharmD, Director of Pharmacy Services at Health New England. Biologic drugs are made from living organisms and are typically more expensive than other medications. Biosimilars are developed to be nearly identical in safety, potency, and efficacy to the original biologic, but at a significantly lower cost. The shift in coverage is intended to make treatment more accessible and financially sustainable for members and employer groups alike. Health New England is directly reaching out to members who are currently prescribed Humira, along with their health care providers and pharmacies, to assist with the transition. The company said it will continue monitoring the biosimilar marketplace to ensure members receive both high-quality care and cost-effective treatment options. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Medscape
3 hours ago
- Medscape
Part D Cancer Drug Launch Prices Soar Past Inflation
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.
